Home › Funds › Foresite Capital Management IV, LLC › CYTK
Foresite Capital Management IV, LLC position in CYTK
CYTOKINETICS INC · Health Care
Foresite Capital Management IV, LLC reported holding 714,695 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$47.1M, representing 18.69% of its reported portfolio and ranking #2 among its reported holdings. Foresite Capital Management IV, LLC has disclosed CYTK holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Foresite Capital Management IV, LLC's CYTK position evolved
Foresite Capital Management IV, LLC first disclosed a stake in CYTK in Q3 2025 at 458,295 shares (US$25.2M). The position peaked in Q2 2026 at 714,695 shares, worth US$60.9M. Across 5 filings, Foresite Capital Management IV, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 714,695 shares valued at US$47.1M. Notable position changes include a 42% increase in Q2 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 458.30K | $25.19M | New |
| Q4 2025 | 458.30K | $29.12M | Hold |
| Q1 2026 | 503.30K | $33.17M | Add |
| Q2 2026 | 714.70K | $60.88M | Add |
| Q3 2026 | 714.70K | $47.11M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 35 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.25B), Avoro Capital Advisors LLC (US$323.0M), Polar Capital Holdings Plc (US$227.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.91M sh · $1.25B · Q3 2026
- Avoro Capital Advisors LLC 4.90M sh · $322.96M · Q3 2026
- Polar Capital Holdings Plc 9.64M sh · $227.69M · Q3 2026
- RTW INVESTMENTS, LP 2.86M sh · $188.63M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.18M sh · $77.79M · Q3 2026
- Integral Health Asset Management, LLC 1.60M sh · $72.50M · Q3 2026
- GW&K Investment Management, LLC 1.02M sh · $67.08M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $64.62M · Q3 2026
- Melqart Asset Management (UK) Ltd 761.54K sh · $50.19M · Q3 2026
- Affinity Asset Advisors, LLC 750.00K sh · $49.43M · Q3 2026
More on Foresite Capital Management IV, LLC
FAQ
How long has Foresite Capital Management IV, LLC held CYTK?
Foresite Capital Management IV, LLC has disclosed CYTK holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Foresite Capital Management IV, LLC's current position in CYTK?
As of Q3 2026, Foresite Capital Management IV, LLC holds 714.70K shares of CYTK (CYTOKINETICS INC), valued at $47.11M, representing 18.69% of its reported portfolio and ranking #2.
Has Foresite Capital Management IV, LLC been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Foresite Capital Management IV, LLC held unchanged its position in CYTK. The position peaked in Q2 2026 at 714.70K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, Polar Capital Holdings Plc, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.